## Michel D'Incan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5442965/publications.pdf

Version: 2024-02-01

713013 932766 1,136 17 10 21 citations h-index g-index papers 22 22 22 941 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid. New England Journal of Medicine, 2002, 346, 321-327.	13.9	552
2	A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study. Journal of Investigative Dermatology, 2009, 129, 1681-1687.	0.3	207
3	Neurological Disorders in Patients with Bullous Pemphigoid. Dermatology, 2007, 215, 187-191.	0.9	122
4	Clinical Criteria for the Diagnosis of Bullous Pemphigoid: A Reevaluation according to Immunoblot Analysis of Patient Sera. Dermatology, 2004, 208, 16-20.	0.9	68
5	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. British Journal of Dermatology, 2021, 184, 1059-1067.	1.4	39
6	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. Blood, 2020, 135, 1058-1061.	0.6	29
7	Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy. Cancer Immunology, Immunotherapy, 2020, 69, 2075-2088.	2.0	19
8	[1231]ICF01012 melanoma imaging and [1311]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models. European Journal of Dermatology, 2015, 25, 29-35.	0.3	15
9	Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice. Contact Dermatitis, 2019, 80, 304-310.	0.8	10
10	International multicentre observational study to assess the efficacy and safety of a $0\text{Å-}5$ mg kg $\hat{a}$ $\hat{a}$ per day starting dose of oral corticosteroids to treat bullous pemphigoid. British Journal of Dermatology, 2021, , .	1.4	8
11	Efficacy of Targeted Radionuclide Therapy Using [1311]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers, 2021, 13, 1421.	1.7	5
12	Phase I study of [1311] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer, 2022, 22, 417.	1.1	5
13	Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study. Journal of the American Academy of Dermatology, 2022, 86, 1293-1300.	0.6	2
14	Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. Acta Dermato-Venereologica, 2022, 102, .	0.6	2
15	Allergic contact dermatitis to guggul in a slimming cream. Contact Dermatitis, 2007, 56, 286-287.	0.8	1
16	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. British Journal of Dermatology, 2021, 184, 356-358.	1.4	1
17	Scalp neurofibromas associated with bone dysplasia. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1233-1235.	1.3	О